152 related articles for article (PubMed ID: 28578178)
1. Frequency and correlates of anticholinergic use among patients with schizophrenia in Denmark: A Nation-wide pharmacoepidemiological study.
Pristed SG; Correll CU; Nielsen J
Psychiatry Res; 2017 Sep; 255():198-203. PubMed ID: 28578178
[TBL] [Abstract][Full Text] [Related]
2. Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study.
Sneider B; Pristed SG; Correll CU; Nielsen J
Eur Neuropsychopharmacol; 2015 Oct; 25(10):1669-76. PubMed ID: 26256007
[TBL] [Abstract][Full Text] [Related]
3. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function.
Ogino S; Miyamoto S; Miyake N; Yamaguchi N
Psychiatry Clin Neurosci; 2014 Jan; 68(1):37-49. PubMed ID: 24102938
[TBL] [Abstract][Full Text] [Related]
4. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment?
Desmarais JE; Beauclair L; Margolese HC
J Psychopharmacol; 2012 Sep; 26(9):1167-74. PubMed ID: 22651987
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study.
Broekema WJ; de Groot IW; van Harten PN
Pharm World Sci; 2007 Jun; 29(3):126-30. PubMed ID: 17333501
[TBL] [Abstract][Full Text] [Related]
6. Anticholinergic use trends in 14,013 patients with schizophrenia from three national surveys on the use of psychotropic medications in China (2002-2012).
Su YA; Yan F; Li Q; Xiang YT; Shu L; Yu X; Ning YP; Zhang KR; Li T; Mei QY; Li KQ; Si TM
Psychiatry Res; 2017 Nov; 257():132-136. PubMed ID: 28755603
[TBL] [Abstract][Full Text] [Related]
7. Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents.
Gjerden P; Slørdal L; Bramness JG
Eur J Clin Pharmacol; 2009 Dec; 65(12):1229-35. PubMed ID: 19644682
[TBL] [Abstract][Full Text] [Related]
8. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.
Miller DD; McEvoy JP; Davis SM; Caroff SN; Saltz BL; Chakos MH; Swartz MS; Keefe RS; Rosenheck RA; Stroup TS; Lieberman JA
Schizophr Res; 2005 Dec; 80(1):33-43. PubMed ID: 16171976
[TBL] [Abstract][Full Text] [Related]
9. Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis.
Sørensen HJ; Jensen SO; Nielsen J
Eur Neuropsychopharmacol; 2013 Aug; 23(8):872-8. PubMed ID: 23642346
[TBL] [Abstract][Full Text] [Related]
10. Use of anticholinergic drugs in patients with schizophrenia in Asia from 2001 to 2009.
Xiang YT; Wang CY; Si TM; Lee EH; He YL; Ungvari GS; Chiu HF; Yang SY; Chong MY; Tan CH; Kua EH; Fujii S; Sim K; Yong KH; Trivedi JK; Chung EK; Udomratn P; Chee KY; Sartorius N; Shinfuku N
Pharmacopsychiatry; 2011 May; 44(3):114-8. PubMed ID: 21491361
[TBL] [Abstract][Full Text] [Related]
11. Anticholinergic use in hospitalised schizophrenic patients in Belgium.
De Hert M; Wampers M; van Winkel R; Peuskens J
Psychiatry Res; 2007 Aug; 152(2-3):165-72. PubMed ID: 17445906
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia.
Ren XS; Huang YH; Lee AF; Miller DR; Qian S; Kazis L
J Clin Pharm Ther; 2005 Feb; 30(1):65-71. PubMed ID: 15659005
[TBL] [Abstract][Full Text] [Related]
13. Atropinic (anticholinergic) burden in antipsychotic-treated patients.
Montastruc F; Benevent J; Touafchia A; Chebane L; Araujo M; Guitton-Bondon E; Durrieu G; Arbus C; Schmitt L; Begaud B; Montastruc JL
Fundam Clin Pharmacol; 2018 Feb; 32(1):114-119. PubMed ID: 28887902
[TBL] [Abstract][Full Text] [Related]
14. Impact of antipsychotics and anticholinergics on autonomic modulation in patients with schizophrenia.
Huang WL; Chang LR; Kuo TB; Lin YH; Chen YZ; Yang CC
J Clin Psychopharmacol; 2013 Apr; 33(2):170-7. PubMed ID: 23422372
[TBL] [Abstract][Full Text] [Related]
15. Lifetime use of psychiatric medications and cognition at 43years of age in schizophrenia in the Northern Finland Birth Cohort 1966.
Hulkko AP; Murray GK; Moilanen J; Haapea M; Rannikko I; Jones PB; Barnett JH; Huhtaniska S; Isohanni MK; Koponen H; Jääskeläinen E; Miettunen J
Eur Psychiatry; 2017 Sep; 45():50-58. PubMed ID: 28728095
[TBL] [Abstract][Full Text] [Related]
16. Anticholinergic Burden and Cognition in Older Patients With Schizophrenia.
Tsoutsoulas C; Mulsant BH; Kumar S; Ghazala Z; Voineskos AN; Menon M; Pollock BG; Rajji TK
J Clin Psychiatry; 2017; 78(9):e1284-e1290. PubMed ID: 29188908
[TBL] [Abstract][Full Text] [Related]
17. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.
Elie D; Poirier M; Chianetta J; Durand M; Grégoire C; Grignon S
J Psychopharmacol; 2010 Jul; 24(7):1037-44. PubMed ID: 19164494
[TBL] [Abstract][Full Text] [Related]
18. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study.
Waddington JL; Youssef HA; Kinsella A
Br J Psychiatry; 1998 Oct; 173():325-9. PubMed ID: 9926037
[TBL] [Abstract][Full Text] [Related]
19. Selective prescribing of atypical antipsychotics.
Breekveldt-Postma NS; Schillevoort I; Nolen WA; Veraart CP; Herings RM
Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):25-30. PubMed ID: 15508132
[TBL] [Abstract][Full Text] [Related]
20. Trends in the Outpatient Utilization of Antipsychotic Drugs in the City of Zagreb in the Ten-Year Period as a Tool to Assess Drug Prescribing Rationality.
Polić-Vižintin M; Tripković I; Štimac D; Šostar Z; Orban M
Psychiatr Danub; 2016 Dec; 28(4):415-419. PubMed ID: 27855434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
